Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 2
2002 12
2003 11
2004 18
2005 6
2006 10
2007 7
2008 8
2009 1
2010 4
2011 4
2012 5
2013 1
2014 2
2016 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.
Menda Y, Kahn D. Menda Y, et al. Semin Nucl Med. 2002 Apr;32(2):92-6. doi: 10.1053/snuc.2002.31564. Semin Nucl Med. 2002. PMID: 11965604 Review.
Several tumors overexpress somatostatin receptors (SSTR) and can thus be imaged with radiolabeled analogues of somatostatin. Tc-99m depreotide is a new radiolabeled somatostatin analogue that shows high affinity for SSTR2, SSTR3, and SSTR5 subtypes. ...Large studies are al …
Several tumors overexpress somatostatin receptors (SSTR) and can thus be imaged with radiolabeled analogues of somatostatin. Tc-99m depre
99mTc-depreotide in the evaluation of bone infection and inflammation.
Papathanasiou ND, Rondogianni PE, Pianou NK, Karampina PA, Vlontzou EA, Datseris IE. Papathanasiou ND, et al. Nucl Med Commun. 2008 Mar;29(3):239-46. doi: 10.1097/MNM.0b013e3282f20e30. Nucl Med Commun. 2008. PMID: 18349794
BACKGROUND AND AIM: (99m)Tc-depreotide is a (99m)Tc-labelled somatostatin analogue, with high affinity for the 2, 3 and 5 subtypes of somatostatin receptors. ...CONCLUSION: (99m)Tc-depreotide can be a useful complementary imaging method in the evaluation of bone inf …
BACKGROUND AND AIM: (99m)Tc-depreotide is a (99m)Tc-labelled somatostatin analogue, with high affinity for the 2, 3 and 5 subtypes of …
99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.
Mena E, Camacho V, Estorch M, Fuertes J, Flotats A, Carrió I. Mena E, et al. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1399-404. doi: 10.1007/s00259-004-1594-x. Epub 2004 Jun 19. Eur J Nucl Med Mol Imaging. 2004. PMID: 15221296 Clinical Trial.
RESULTS: 99mTc-depreotide uptake in the primary tumour was seen in 19 of the 20 patients. ...Furthermore, whole-body 99mTc-depreotide scintigraphy may disclose extra-osseous disease....
RESULTS: 99mTc-depreotide uptake in the primary tumour was seen in 19 of the 20 patients. ...Furthermore, whole-body 99mTc-depreot
99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer.
Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. Rodrigues M, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):3997-4000. doi: 10.1210/jc.2006-0825. Epub 2006 Aug 8. J Clin Endocrinol Metab. 2006. PMID: 16895961
BACKGROUND: Papillary and follicular thyroid cancer were found recently to express somatostatin receptors (SSTRs). (99m)Tc-depreotide binds with high affinity to SSTRs 2, 3, and 5. AIM: The aim of this study was to evaluate the feasibility of applying (99m)Tc-depreotide
BACKGROUND: Papillary and follicular thyroid cancer were found recently to express somatostatin receptors (SSTRs). (99m)Tc-depreotide
99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.
Bushnell DL, Menda Y, Madsen MT, Link BK, Kahn D, Truhlar SM, Juweid M, Shannon M, Murguia JS. Bushnell DL, et al. Nucl Med Commun. 2004 Aug;25(8):839-43. doi: 10.1097/01.mnm.0000126628.01919.f9. Nucl Med Commun. 2004. PMID: 15266180 Clinical Trial.
BACKGROUND: 99mTc-depreotide (NeoTect) is a synthetic somatostatin analogue, which binds to somatostatin receptor (SSTR) subtypes 2, 3 and 5. ...RESULTS: Paired CT and 99mTc-depreotide images for three patients with indolent and six with aggressive NHL revealed abno …
BACKGROUND: 99mTc-depreotide (NeoTect) is a synthetic somatostatin analogue, which binds to somatostatin receptor (SSTR) subtypes 2, …
The role of 99mTc-depreotide in the management of neuroendocrine tumours.
Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C, Hochhauser D, Buscombe J, Caplin ME. Shah T, et al. Nucl Med Commun. 2008 May;29(5):436-40. doi: 10.1097/MNM.0b013e3282f50747. Nucl Med Commun. 2008. PMID: 18391727
To determine the usefulness of Tc-depreotide scintigraphy for highlighting lesions that may be missed by OctreoScan and/or CT/MRI imaging. ...Thirty-two percent of these same patients had significantly positive Tc-depreotide scans (Krenning score> or =2), with th …
To determine the usefulness of Tc-depreotide scintigraphy for highlighting lesions that may be missed by OctreoScan and/or CT/MRI ima …
Pre-clinical evaluation of a new indirectly labeled 99mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator.
Yu F, Lü ML, Zhang XP, Fu D, Hou M, Cai HD, Li D, Wang J, Yuan XY, Lü ZW, Dong F. Yu F, et al. Chin Med J (Engl). 2012 Jul;125(14):2538-42. Chin Med J (Engl). 2012. PMID: 22882936
This research was to study the preclinical effect of a new (99m)Tc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide, indirect (99m)Tc labeling of depreotide using HYNIC as a bifunctional chelator. ...RESULTS: The molecular of synthesize depreotide was …
This research was to study the preclinical effect of a new (99m)Tc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide, indirect …
Therapeutic effect of 188Re-MAG3-depreotide on non-small cell lung cancer in vivo and in vitro.
Yu F, Lv M, Cai H, Li D, Yuan X, Lv Z. Yu F, et al. Int J Clin Exp Pathol. 2013;6(3):421-30. Epub 2013 Feb 15. Int J Clin Exp Pathol. 2013. PMID: 23411669 Free PMC article.
The cancer growth continued after treatment with 188Re or MAG3-depreotide alone, while the cancer growth was markedly inhibited after 188Re-MAG3-depreotide treatment when compared with control group. CONCLUSION: 188Re-MAG3-depreotide can inhibit the prolifera …
The cancer growth continued after treatment with 188Re or MAG3-depreotide alone, while the cancer growth was markedly inhibited after …
Experimental study of 99mTc-depreotide preparation and its affinity with A549 cell.
Xia W, Zhang X, Yu F, Wang P, Cai H, Hou R, Wang G, Yuan X, Lv Z. Xia W, et al. Front Biosci (Landmark Ed). 2011 Jun 1;16(7):2527-39. doi: 10.2741/3870. Front Biosci (Landmark Ed). 2011. PMID: 21622193 Free article.
The (99m)Tc-labeled agent, ((99m)TcO)depreotide, has received regulatory approval in the United States and Europe for use in the detection of cancer. ...The results showed that the optimal conditions for labeling depreotide with (99m)Tc was found to be below 15 C at …
The (99m)Tc-labeled agent, ((99m)TcO)depreotide, has received regulatory approval in the United States and Europe for use in the dete …
Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules.
Halley A, Hugentobler A, Icard P, Porret E, Sobrio F, Lerochais JP, Bouvard G, Zalcman G, Agostini D. Halley A, et al. Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1026-32. doi: 10.1007/s00259-005-1812-1. Epub 2005 May 5. Eur J Nucl Med Mol Imaging. 2005. PMID: 15877227 Clinical Trial.
METHODS: Twenty-eight patients without any history of cancer and presenting an SPN (0.8-3 cm in size) underwent FDG PET and depreotide SPECT. Depreotide SPECT and FDG PET were performed on a double-head gamma camera and a dedicated PET scanner respectively. ...FDG P …
METHODS: Twenty-eight patients without any history of cancer and presenting an SPN (0.8-3 cm in size) underwent FDG PET and depreotide
96 results